🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
10.77
+0.28 (2.67%)
Nov 18, 2026, 4:00 PM EST - Market closed
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

CMS set a $1,000 TearCare SmartLids supply-code price, supporting payer discussions; management expects additional coverage within quarters. TearCare remains early in a large market, while OMNI Ultra launches in Q4 2026 with a larger tailwind expected in 2027.

Tom Stephan
Analyst, Stifel

Morning, everyone. Tom Stephan, Stifel Research. Excited to have Sight Sciences back at the conference this year. Paul, Jim, great to see you guys. Appreciate you joining.

Paul Badawi
Founder and CEO, Sight Sciences

Good to see you, Tom.

Jim Rodberg
CFO, Sight Sciences

Thanks.

Tom Stephan
Analyst, Stifel

All right. I'll dive right into questions, and I'll start with dry eye, and I'll begin with what's topical, in my view. Saw that CMS established a practice expense supply code for TearCare. Paul, maybe for you, can you explain to us what occurred, and importantly, what impact this has on TearCare?

Paul Badawi
Founder and CEO, Sight Sciences

Sure. Yeah, we're excited about the supply code for the TearCare SmartLids from CMS. We engaged with CMS earlier in the year to establish a supply code, and the result to that effort, pleased to share that CMS arrived at an appropriate price point for the TearCare SmartLids at $1,000. This is important in our market access journey. Obviously, CMS, Medicare's the largest payer in the country, so to have a nationally recognized, validated kind of reference point on the pricing obviously creates a good environment for us to have transparent and consistent conversations with additional payers, notably the additional MACs that we're engaged with.

Tom Stephan
Analyst, Stifel

Got it. Got it. Does this in any way help with those payer discussions and deliberations? In other words, does United see this as further validation of a product, or is a practice expense supply code sort of less of a consideration?

Paul Badawi
Founder and CEO, Sight Sciences

First, we continue to be engaged with both MACs and commercial payers, both national commercial payers, as you referenced, as well as regional commercial payers. Those conversations are ongoing, constructive. I feel like we're making great progress. I think the supply code is relevant to all of those conversations. I think there's more immediate relevance to the MACs, just given the relationship between CMS and the Medicare Administrative Contractors. Obviously, each MAC will ultimately arrive at its own coverage policy and fee schedule, but to have this standard in place from CMS, again, the largest payer in the country, is going to be helpful both for MACs and commercial payers.

Also, I'd say, imagine this, Tom, as we're growing commercially in First Coast and Novitas, and as we bring on additional MACs, think about all of those customers that are making TearCare part of their regular interventional eye care practice and within their practices. So when you have those kinds of customers who are seeing the really strong clinical benefits for patients and the importance of this procedure in their practice grows, they will help advocate for additional coverage over time. So, it's relevant in multiple ways.

Tom Stephan
Analyst, Stifel

Got it.

Paul Badawi
Founder and CEO, Sight Sciences

The supply code, that is.

Tom Stephan
Analyst, Stifel

Got it. That's helpful. On payer discussions, Paul, you noted making good progress. I know it's a moving target, visibility not overly high, but I guess today, what are the main areas of pushback or resistance from payers, maybe in still viewing TearCare as investigational and not a covered procedure? I guess, what gives you confidence that these aren't more permanent barriers or hurdles to getting TearCare ultimately covered?

Paul Badawi
Founder and CEO, Sight Sciences

Yeah. I think I would say it's a process. We're creating a new category. We're creating not only a new category in medicine with interventional dry eye and reimbursed procedural dry eye, but for payers to cover something new, it does take time. I think we have. Our conversations are very constructive. We continue to feel very bullish about getting additional payers in the coming quarters. Clinical evidence is very strong with SAHARA. The health economics is very strong. So we don't feel like we have any official barrier. What I do think we need to continue to have our happy TearCare customers continuing to submit high-quality claims to demonstrate that unmet need, right? The more that our customers raise awareness at payers and the more pressure is applied, demonstrating that unmet need, I think will generate results faster. So that's where we're focused as a company.

We're continuing to invest. We have a world-class market access team, very happy with the team there, and they're continuing to add resources in market access. So, our quality team engaging with customers who love TearCare, getting more claims submitted to payers, to the MACs, to commercial payers, doing more of that, again, resulting in more pressure so that policies are ultimately created or fee schedules.

Tom Stephan
Analyst, Stifel

Got it. Super helpful. I don't want to put words in your mouth. Does this feel like mostly a matter of when and not if? Payer success, acceptance, it is obviously critical. You mentioned it takes time, it is a process. It sounds like there are not necessarily instances of payers drawing a line in the sand of sorts, perhaps requesting more data. It is simply a process, claims, and hopefully when, it is simply just when and not if. Is that fair?

Paul Badawi
Founder and CEO, Sight Sciences

Yeah, I think it is. I think the payers have been clear. I think they have responded very well to our SAHARA clinical data. It is a two-year RCT in dry eye against the standard of care, so I think that has been very well received. I think the health economics publications have been very well received. The story makes sense. I think it is a matter of time. We continue to believe that. We continue to have great conversations. It is hard to predict these things, when you can actually get from the red zone into the end zone. But we feel like, and we have said it before, we will say it again, we feel like we are within quarters of getting additional coverage and/or fee schedules.

Tom Stephan
Analyst, Stifel

Got it. So, within quarters, it sounds like maybe some late-stage conversations. Do we think about that as more Medicare MAC-oriented perhaps, or are there commercials layered into that as well? Any sense for kind of like the mix in terms of who is further along or later stage?

Paul Badawi
Founder and CEO, Sight Sciences

Our market access team is engaged with all of the above, Tom, so I would say we have some pretty mature MAC conversations. We have some very healthy commercial conversations as well. Which one would be the next one? Honestly, hard to predict. If I was guessing, it would just be My answer might change tomorrow depending on some feedback you get.

Tom Stephan
Analyst, Stifel

Sure

Paul Badawi
Founder and CEO, Sight Sciences

from a payer on a Thursday.

Tom Stephan
Analyst, Stifel

Okay.

Paul Badawi
Founder and CEO, Sight Sciences

Both MAC conversations, commercial conversations are progressing nicely. Our market access team feels very confident. It is a matter of time.

Tom Stephan
Analyst, Stifel

Got it. That is great. I guess kind of sticking with reimbursement, with TearCare, I have in quotes, kind of turning back on after a pause of sorts in 2025, my first question is the volume growth we are seeing now all or vast majority covered procedures, or how much of the volume growth over the past several quarters is also simply the cash pay volumes kind of turning back on as well? Does that question sort of make sense?

Paul Badawi
Founder and CEO, Sight Sciences

The simple answer, the vast majority of our business, like vast majority of our business is our covered paid procedures.

Tom Stephan
Analyst, Stifel

Okay.

Paul Badawi
Founder and CEO, Sight Sciences

Little cash pay.

Tom Stephan
Analyst, Stifel

Okay.

Paul Badawi
Founder and CEO, Sight Sciences

We still have, obviously, we have important customers who need TearCare in non-covered areas, and they've continued to use TearCare because it's a very important part of their practice in the cash pay world. All the growth that we're seeing and the exciting growth within the Novitas and First Coast regions, those are reimbursed procedures. Jim, do you want to add anything to that?

Jim Rodberg
CFO, Sight Sciences

I think that's the big thing is the unlock and the growth this year is from reimbursement progress.

Tom Stephan
Analyst, Stifel

Yeah.

Jim Rodberg
CFO, Sight Sciences

That's the unlock and growth for the future, is continued reimbursement progress.

Tom Stephan
Analyst, Stifel

Got it. Really encouraging. I have a line of questions here, so this will arrive at a point. My follow-up would be, 15 million covered lives today, essentially. So what do you guys view as the potential TAM from a covered live standpoint, maybe as we think about other dry eye drugs and the coverage that they've achieved? I am just curious where you believe that 15 million potentially goes over time.

Paul Badawi
Founder and CEO, Sight Sciences

Yeah. What we are looking at today, Tom, our existing TAM within First Coast and Novitas is a very large opportunity by itself. So, we estimate about 700,000-800,000 moderate to severe MGD patients in First Coast and Novitas. Based on our 2026 performance and guide, that is likely 1%-2% penetration of our current TAM, our current reimbursed TAM.

Tom Stephan
Analyst, Stifel

Right.

Paul Badawi
Founder and CEO, Sight Sciences

So there is a ton of runway over the coming years just within First Coast and Novitas. Obviously, as we layer on additional payers, both go broader with additional MACs elsewhere in the country, and then go deeper with commercial payers, we can drive up that performance. But the current TAM we have in front of us right now, today, is large and pretty much unpenetrated.

Tom Stephan
Analyst, Stifel

Got it. Okay, great. If I were to take it a little bit of a step further, and a lot of these are sort of hypotheticals, but covered lives today, again, basically maybe in that 15 million range, you are probably going to exit the year run rating at 20,000 covered procedures annualized.

If we conservatively say that covered lives can reach, and conservatively, only 75 million, up 5x from today, that could imply at least 100,000 procedures, if we think about the 20,000 within the 15 million denominator. If covered lives were 150 million, that could imply 200,000 procedures. Is this a fair framework? Talk us through how the company thinks about peak sales for TearCare.

Paul Badawi
Founder and CEO, Sight Sciences

Yeah. Tom, I think that's a very fair framework. I think what you're getting at, and we will support with some other TAM information, is that there's orders of magnitude of a TAM opportunity in front of us from where we are today. A multiple, a significant multiple.

If we have, the way we look at it, 700,000- 800,000 MGD patients within First Coast and Novitas, moderate to severe, there's 7 million- 8 million moderate to severe MGD patients nationally. Again, getting back to your order of magnitude, that is what we have in front of us. Again, we are probably 1%-2% penetrated in our existing reimbursed TAM.

Nationally, there's probably a 10x, going from 700,000- 800,000 to 7 million- 8 million moderate to severe MGD patients in the country. You can see how much runway there is, not just today within First Coast and Novitas, but as our market access team generates additional successful payer policies or fee schedules, over time, the TAM continues to expand. I'll also emphasize the fact that we are very focused on several states right now, perfecting the commercial model in First Coast and Novitas in states like Texas, Florida, Pennsylvania, New Jersey, Maryland, et cetera. It's really allowed us to sharpen our go-to-market strategy, who we hire, which customers are the best early adopters.

We've gotten far more efficient and effective in the past year, so we can't wait until we have additional coverage and we can go elsewhere in the country and leverage all of the learning that we've benefited from over the past year and launch in those areas with experienced commercial excellence.

Tom Stephan
Analyst, Stifel

Got it. That's great. Stifel Research has published an estimate of about $100 million in peak sales for TearCare, a bit over 100,000 procedures, ASP maybe in the $800 range. Paul, your commentary on the TAM size, orders of magnitude larger than what it is today, does that suggest, and again, you're run-rating 20,000 covered procedures, does that suggest you'd feel confident in that $100 million, possibly even as a floor as investors are trying to think about that peak sales number?

Paul Badawi
Founder and CEO, Sight Sciences

I would not be confident in that number, actually. I would be confident in something higher.

Tom Stephan
Analyst, Stifel

Sure.

Paul Badawi
Founder and CEO, Sight Sciences

I think if you take that run rate, and you take the TAM we were discussing, if we're 1%-2% penetrated right now in our existing reimbursed TAM, and the total potential TAM is an order of magnitude more than that, it should be a lot larger than that.

Tom Stephan
Analyst, Stifel

Perfect. Super helpful.

Paul Badawi
Founder and CEO, Sight Sciences

Fair, Jim?

Jim Rodberg
CFO, Sight Sciences

Yeah, the oppor-

Paul Badawi
Founder and CEO, Sight Sciences

Jim's math is better than mine.

Jim Rodberg
CFO, Sight Sciences

Yeah. The opportunity is very, very significant, as Paul laid out, so we're excited about the opportunity.

Tom Stephan
Analyst, Stifel

Perfect. All right, to shift gears a little bit within TearCare, I wanted to ask about customers. So in 3Q, I believe there were a bit over 200 active customers, but the company is seemingly shifting away, correct me if I'm wrong, slightly from optometry, at least on a relative basis, maybe more towards ophthalmology. My first question, what does the company view as the target customer opportunity figure, maybe assuming broad reimbursement and coverage across the country?

Paul Badawi
Founder and CEO, Sight Sciences

I'll just say something, and Jim, you want to pile on. I wouldn't describe it, Tom, as shifting away from anything. I would say that we have, because of the fact that we have Medicare MAC coverage right now, First Coast and Novitas, so Medicare-age patients, it's an interventional procedure. I would say that the world of ophthalmology and collaborative care practices, which include ophthalmology and optometry, that market segment is pulling us.

Tom Stephan
Analyst, Stifel

Right

Paul Badawi
Founder and CEO, Sight Sciences

It is more than moving away, because I think in due course, this market, TearCare, is going to be very successful in ophthalmic practices, collaborative care practices, and optometric practice. It just so happens that I think the nature of our first reimbursement with Medicare and the fact that it's an interventional procedure on Medicare-age patients, it has a lot of similarities with things like cataract surgery, which is an interventional procedure typically on Medicare-age patients, or glaucoma surgery that we have a significant presence in with OMNI, which is an interventional procedure typically on Medicare-age patients. There are all these synergies with our existing business, as well as the fact that a lot of interventional ophthalmologists intervene on Medicare-age patients. It is very intuitive that that market segment.

Tom Stephan
Analyst, Stifel

Sure

Paul Badawi
Founder and CEO, Sight Sciences

the interventional ophthalmology market segment, would adopt TearCare earlier, faster. So it's more of a market pull thing than a shift away from. Does that make sense?

Tom Stephan
Analyst, Stifel

Yeah. No, totally. So, makes perfect sense. So, I guess, we look back in the model. If the previous peak active customers, I think on a quarterly basis, was nearly 400, can you get back to that near to intermediate term, or are there potential limitations? I guess I'm trying to get at, how does the active customer ramp look with TearCare as reimbursement kind of comes online? If we're doing more of a bottoms-up approach from a modeling standpoint, obviously customers times utilization. Any comment there?

Jim Rodberg
CFO, Sight Sciences

Yeah, I think it's important, Tom, to look at two things here. One, the progression we've had this year in active accounts. 96 in the first quarter, 176 in the second, 222 in the third quarter. So, we've grown active accounts nicely, all while increasing utilization at the same time. So for us, I think it's less about a pure active account number. It's how do we incrementally continue to grow the account base in high-quality-

Tom Stephan
Analyst, Stifel

Sure

Jim Rodberg
CFO, Sight Sciences

high-utilization accounts. And I think the progression so far has proven we've been successful there, and as Paul mentioned, a lot of runway to go. So, I think, rather than a specific target, the trend is in the right direction, and we're focused on adding high-quality accounts continually.

Tom Stephan
Analyst, Stifel

Got it. That's helpful. Jim, maybe I'll stick with you, last one or two on TearCare. Guidance for the full year implies, I think, roughly flattish revenue Q3 to Q4, yet we have seen over $1 million of sequential growth from Q1 to Q2 and Q2 to Q3. Anything to call out on that, as to maybe why that million-dollar-plus sequential growth wouldn't continue in the fourth quarter? Is there seasonality, or there may be unique ordering patterns in the third quarter that create a high base? Just any comment on kind of the implied guide for Q4.

Jim Rodberg
CFO, Sight Sciences

Yeah, nothing to call out here other than our typical approach to guidance, where we want to set achievable targets we can deliver with confidence. This is the approach we've taken all year. The opportunity is huge, but we're early in this, so we want to be diligent and disciplined in our guide, and we feel really good about the underlying business and the metrics and the progress we've made this year, and the opportunity in front of us. No, nothing to call out that would point to anything other than-

Paul Badawi
Founder and CEO, Sight Sciences

Strong momentum

Jim Rodberg
CFO, Sight Sciences

strong momentum and set up for the fourth quarter.

Tom Stephan
Analyst, Stifel

Makes perfect sense. Paul, maybe finish with you on TearCare. Early in this initiative, very encouraging progress out of the gate. What would you say the street investors maybe still aren't fully appreciating as we think about TearCare more long term? What would you like to take this opportunity to maybe emphasize about TearCare that you think should gain greater attention and focus?

Paul Badawi
Founder and CEO, Sight Sciences

Sure. Yeah. I do believe the street investors are actually focused more and more on TearCare every day, so I think it is resonating, and the story is becoming pretty darn clear. I think the growth, the underlying metrics, account growth, utilization increasing with account growth, it's sticky. It's a great business model. It's sticky. I think that's clear now, Tom. I think what people are waiting for, I think additional market access.

I think any analysis of our Well, look, it's obviously early days, but if you analyze our commercial performance over the past couple of quarters within a very small subset of our total potential TAM, it's very interesting. It's a really, really interesting business model. I think the unlock of continued value creation and value acceleration will be expanding the TAM, broadening the TAM beyond First Coast and Novitas, but then also deepening it with commercial payers. As you can imagine, Tom, think about the commercial infrastructure we've developed over the past year. We're extremely proud of the quality of the team, the commercial team we've built within the First Coast and Novitas states. Really great team, really great work getting done, really great partnerships with accounts within those states.

I think it's just we cannot wait to leverage that learning and experience and grow the business with additional payers, both within those states and outside, elsewhere in the country. The investments have been made in First Coast and Novitas. As payers come online in those states, you have active TearCare customers in those states who love doing TearCare on Medicare. I was just down in Florida earlier this week, and customers are saying, "When are you going to get some commercial payers? Because I love doing TearCare on my Medicare patients, and I want to expand it to the commercial patients." The model's really interesting. There's a lot of leverage to be had over time, where we've spent on commercial infrastructure targeting Medicare, and then you just layer on TAM with commercial payers.

Tom Stephan
Analyst, Stifel

Yep. Perfect. Last one here. So, maybe to wrap it all up a little bit on the TearCare side, you've shown early days this is obviously a large opportunity. A lot of people in the U.S. with dry eye. You're showing initial traction. This is real, and as a company, you've been pushing for this, I mean, for years, and it's now taking hold. There is a fair amount of competitors in this space. There's LipiFlow, there's iLux, maybe some others. Is there a risk that they see you guys unlocking this market and trying to make this push away from cash pay and into reimbursed procedures? Or are there limitations from those competitors? Maybe it's clinical data, or other factors, that could kind of keep this opportunity all to Sight?

Paul Badawi
Founder and CEO, Sight Sciences

Yeah, I think anytime a new market is created and lots of value is created, it'll grab the attention of others, and that's normal. We'd be surprised if others at some point in time didn't at least try to come into the market that we're creating. That's all normal. We have a high bar for ourselves, so we're not sitting idle. We continue to elevate the bar. We've already done a lot in this category that's going to be hard, I think, hard to compete with. The clinical bar with SAHARA, the two-year RCT, was a tough study. Big investment, significant risk we took. Thankfully, it was highly successful. So I think we've set a pretty high clinical bar for any potential new entrants. I think the technology we've developed over the past decade, we've been working nonstop on iterating the technology.

We have a new version of TearCare coming out next year. So it's kind of hard to keep up, I'd say, with our technology development. I think we have best-in-class MGD technology. Yeah, and we're going to continue building a large clinical data, evidence, and support for TearCare. We'll continue to add to that. So, we're going to keep moving. I would be surprised if five years or 10 years from now, there aren't other folks trying to get into the category that we're creating, but that's okay.

Tom Stephan
Analyst, Stifel

Got it. Okay, perfect. I'll pivot to glaucoma in the last handful of minutes, and I'll start with Ultra. I guess I'll jump kind of right to one of my main questions here, but should we be thinking about OMNI Ultra as sort of a true incremental growth accelerator for the glaucoma business? I guess within that, any comments on both volume and price around Ultra would be helpful.

Paul Badawi
Founder and CEO, Sight Sciences

Yeah, we're excited about Ultra, Tom. We're launching it as we speak. Again, I was down in Florida, not just for TearCare, but also for some Ultra cases, was in the operating room with our team and some of our top customers in Florida, and the Ultra cases were perfection. Very happy with the performance. We obviously hold a high bar for our high technology bar, and I think Ultra builds on the legacy of the OMNI platform. It's a top product in MIGS, the number one in implant-free MIGS. We've set the bar high, and Ultra offers single-pass canaloplasty, so more efficiency and less intraocular movements, which is good for the patient, good for the doctor. TruSync Plus technology, viscoelastic delivery on both advancement and retraction of the catheter. That's a welcome feature by surgeons, helps with the overall procedure.

Lastly, something we've been surprised with, the response for markings on the catheter that allow for enhanced visualization during surgery. Surgeons have responded very favorably to the markings we've placed on the catheter to give the surgeon an idea of where they are in the procedure, how much of the procedure they've completed, how much of the procedure remains. It's smooth, it's working really well. We're excited. We're launching it right now, training surgeons across the country. I'd expect it to show up in Q4. Obviously, 2027 is where we'll see the bigger tailwind from Ultra. Call it like a nice breeze.

Tom Stephan
Analyst, Stifel

Sure

Paul Badawi
Founder and CEO, Sight Sciences

in Q4, with a tailwind in 2027.

Tom Stephan
Analyst, Stifel

Perfect. Jim, maybe for you, I'll ask sort of a similar question on glaucoma that I did for dry eye. Glaucoma seasonality, it's been a bit wonky for OMNI the last few years. Typically in MIGS, Q4 up sequentially from Q3, yet the guidance at the midpoint implies down quarter-over-quarter glaucoma revenue from Q3 to Q4. It sounds like OMNI Ultra, nice breeze, I think were your words, Paul.

Paul Badawi
Founder and CEO, Sight Sciences

Q4 tailwind in 2027.

Tom Stephan
Analyst, Stifel

Tailwind in 2027.

Paul Badawi
Founder and CEO, Sight Sciences

Yeah.

Tom Stephan
Analyst, Stifel

Perfect. Perfect. Jim, was there something in October trends that maybe gave you pause around raising to a higher range for the implied 4Q? Just curious how we should be interpreting sort of that down sequential glaucoma revenue growth at the midpoint, or is it kind of a typical playbook?

Jim Rodberg
CFO, Sight Sciences

Yeah, not at all. Nothing in October that would signal anything other than what we've seen in the business year to date, and that is strength. So, record number of active accounts coming out of Q3, OMNI Ultra launching here in Q4. So, we like the setup in Q4, and it's our typical approach to guidance, so feeling good about the momentum and strength of that business.

Tom Stephan
Analyst, Stifel

Fantastic. Jim, I will stick with you for the last question, just from a profitability standpoint and a P&L standpoint. Adjusted OpEx for 2026 guiding to year-over-year growth of, I think, it is $5 million on a dollar basis this year, if I have that right. 2027 probably would expect increased investments around key initiatives, notably in dry eye. We are modeling a bit over $100 million in adjusted OpEx next year, so up $8 million year-over-year from this year's midpoint. I mean, is that a realistic starting point as we kind of exit this year? Or maybe just talk us through kind of elements of adjusted OpEx in 2027, as we are kind of dialing in our models.

Jim Rodberg
CFO, Sight Sciences

Yep. So, not going to guide yet today on 2027.

Tom Stephan
Analyst, Stifel

That is right.

Jim Rodberg
CFO, Sight Sciences

We will get into that on an upcoming call. However, what I will say is we expect revenue growth to continue to outpace expense growth. We have got investments behind the top growth drivers like IDE, as you mentioned, and we are excited about the opportunity, but we will be disciplined and expect revenue to outpace the expense growth as we get into 2027 as well.

Tom Stephan
Analyst, Stifel

Perfectly fair.